Bloomios Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
BLMS Over the counter 2833

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bloomios Inc

Bloomios to Present at the 2022 LD Micro Invitational June 7-9 - May 25th, 2022 12:31 pm
Bloomios Expands Production Capacity by 300%, Setting Stage for Strong Growth in 2022 - May 18th, 2022 12:31 pm
Bloomios Reports 2021 Revenue at Record $8.5 Million, up from $1.3 Million in 2020 - Apr 19th, 2022 12:31 pm
Bloomios Selected as Exclusive Manufacturer for DRYWORLD's New Athletic Performance CBD Product Line - Mar 31st, 2022 8:40 pm
DRYWORLD Struts into Multi-Billion Dollar CBD Market - Mar 31st, 2022 8:20 pm
Bloomios Engages CMA to Lead New Investor and Public Relations Campaign - Mar 16th, 2022 3:12 pm
Bloomios Begins Trading on OTCQB Venture Market as BLMS, as Hemp-Derived Cannabinoid Product Sales Exceed $8 million - Mar 15th, 2022 9:30 am
Bloomios to Exhibit Turnkey Private Label Solution for Hemp-Derived Products at ASD Market Week, February 27 to March 3, 2022 - Feb 28th, 2022 4:54 pm
Bloomios Announces its' Form S-1 Registration Effective Allowing the Company to Raise up to $6.5 Million in Growth Capital - Jan 31st, 2022 2:00 pm
Bloomios Shareholder Update & Growth Strategy - Nov 17th, 2021 5:34 pm